전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved255 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleInstitut BergoniéPhase 2

durvalumab (Imfinzi, Association of lurbinectedin and durvalumab)

Small Cell Lung Cancer; Platinum-Sensitive Lung Small Cell Carcinoma · Small Cell Lung Cancer

#SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Platinum-SensitiveLungSmallCellC+1
Trials 1Status Discontinued
CGTLimited DatastaleRochePhase 1

atezolizumab (Tecentriq, Atezolizumab and Interleukin-12 Gene Therapy)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Autologous B7-H3 CAR T (Autologous B7-H3 CAR T)

Extensive-Stage Small Cell Lung Cancer; Extrapulmonary Neuroendocrine Carcinoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleNavire Pharma Inc., a BridgeBio…Phase 1

nivolumab (Opdivo, BBP-398 with nivolumab)

Non Small Cell Lung Cancer; Solid Tumor · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase1#monoclonal-antibody#SolidTumor+1
Trials 1Status Discontinued
CGTLimited DatastaleAllorunning TherapeuticsPhase 1

BCMA/CD19-targeted allogeneic CAR-T (BCMA/CD19-targeted allogeneic CAR-T)

Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCT; Newly Diagnose… · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleBristol-Myers SquibbPhase 3

BMS-986012+Nivolumab (BMS-986489, BMS-986489 (BMS-986012+Nivolumab))

Extensive-Stage Small Cell Lung Cancer · Extensive-Stage Small Cell Lung Cancer

#Extensive-StageSmallCellLungCanc#Antibody#Phase3#monoclonal-antibody#Bristol-Myers
Trials 1Status Recruiting
AntibodyLimited DatastaleNational Cancer Center, KoreaPhase 2

nivolumab (Opdivo, CA and Nivolumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#National
Trials 1Status Active
CGTLimited DatastaleInstitute of Hematology & Blood…Phase 1

CAR T cells chimeric antigenreceptor cells (CAR T cells chimeric antigenreceptor cells)

Relapsed/Refractory B-cell Non-Hodgkin Lymphoma; Relapsed/Refractory B-cell ALL · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleGuangzhou Anjie Biomedical Tech…Phase 2

CAR-T combining PD-1 Knockout (CAR-T combining PD-1 Knockout)

Lung Neoplasm Malignant; Non-small Cell Lung Cancer · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleYake Biotechnology Ltd.Phase 2

CART therapy (CART therapy)

Neuroblastoma (NB); Desmoplastic Small Round Cell Tumor (DSRCT) · Neuroblastoma (NB)

#NeuroblastomaNB#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleKite, A Gilead CompanyPhase 1

CART-TnMUC1 (CART-TnMUC1)

Non-Small Cell Lung Cancer; Ovarian Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleFundación Pública Andaluza para…Phase 2

CARTemis-1 (CARTemis-1)

Multiple Myeloma; Allogeneic Stem Cell Transplantation · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleSabz BiomedicalsPhase 1

CD19 CAR engineered autologous T-cells (CD19 CAR engineered autologous T-cells)

Relapsed B Cell Acute Lymphoblastic Leukemia (ALL); Refractory B Cell Acute Lymphoblastic Leukemia (ALL) · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 2

CD19 and CD22 targeted prime CAR-T cells (CD19 and CD22 targeted prime CAR-T cells)

B-ALL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBambino Gesù Hospital and Resea…Phase 1

CD19-CAR_Lenti_ALLO (CD19-CAR_Lenti_ALLO)

B-cell Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleMedical University of South Car…Phase 2

CD19-CD34t metabolically programmed CAR transduced T-cells (CD19-CD34t metabolically programmed CAR transduced T-cells)

B-cell Non Hodgkin Lymphoma; Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBioray LaboratoriesPreclinical

CD19-UCART (CD19-UCART)

Acute Lymphoblastic Leukemia (ALL); Non Hodgkin Lymphoma (NHL) · CD19

#CD19#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleBaylor College of MedicinePhase 1

CD19.CAR-aNKT cells (CD19.CAR-aNKT cells)

Refractory B-Cell Non-Hodgkin Lymphoma; Refractory B-Cell Small Lymphocytic Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 2

CD22 CAR-transduced T cells (CD22 CAR-transduced T cells)

Acute Lymphoblastic Leukemia; B-All · CD22

#CD22#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleCenter for International Blood …Phase 2

CD33CART allogeneic (CD33CART allogeneic)

Acute Myelogenous Leukemia · CD33

#CD33#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting

7 / 13 pages

← PreviousNext →